Myseum, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Myseum, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $550 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $436 | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $672 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $46.2K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $4.4K | Mar 31, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.61M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.24M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($8.40M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.14M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($10.83M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($979.5K) | Mar 29, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.49M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($3.22M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($8.78M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($12.23M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($10.84M) | Mar 31, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $166.7K | Mar 30, 2026 |
| FY2025 | Aug 27, 2024 | $166.7K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $1.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $515.0K | Mar 29, 2024 |
| FY2023 | Jul 19, 2022 | $185.6K | Mar 29, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.27M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($4.81M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($6.53M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($7.26M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($8.45M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($1.10M) | Mar 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.5K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $49.5K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $44.5K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $56.0K | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.20M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $5.37M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $13.11M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $20.82M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $744.3K | Mar 29, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $630.3K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $406.6K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $557.1K | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | $731.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $162.0K | Mar 29, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.10M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $6.88M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $6.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $12.56M | Mar 29, 2024 |
| FY2023 | Dec 31, 2021 | $20.08M | Mar 29, 2024 |
| FY2022 | Dec 31, 2020 | $582.3K | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($339.9K) | Mar 29, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($54.98M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($52.37M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($48.13M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($39.73M) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | ($27.59M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($16.76M) | Mar 29, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $749.0K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $767.0K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $953.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.73M | Mar 29, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (6) | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.26M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 3.01M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 2.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 2.06M | Mar 29, 2024 |
| FY2022 | Dec 31, 2021 | 19.60M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 12.73M | Mar 29, 2022 |